

Pediatric CIRB Meeting Agenda

April 9, 2026

I. Initial Review

PBTC-048, Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction with Radiation Therapy for children with Newly Diagnosed DIPG (Version Date 03/09/26)

II. Initial Review

PEPN2513, A Phase 1 trial of the menin inhibitor SNDX-5613 (Revumenib) (IND# TBD, NSC# 852942) for maintenance therapy after allogeneic hematopoietic stem cell transplantation in pediatric patients with Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia (Version Date 02/19/26)

III. Amendment Review

PBTC-060, A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (Version Date 02/20/26)

IV. Amendment Review

PEPN1924, A Phase 1/2 study of DS-8201a in children, adolescents, or young adults with recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor (Version Date 03/11/26)

V. Continuing Review

ACNS2021, A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (Version Date 03/29/24)

VI. Continuing Review

AOST2031, A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma (Version Date 12/16/25)

VII. Continuing Review

ANHL1931, A Randomized Phase 3 trial of Nivolumab(NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma (Version Date 07/30/25)

VIII. Continuing Review

AGCT1531, A Phase 3 Study of Active Surveillance for Low risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors (Version Date 01/08/26)

IX. Continuing Review

AREN2231, Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) (Version Date 01/28/26)
